Cipla Limited

NSE:CIPLA
Q1 FY2025 2024-07-26
QUARTERLY REVENUE: INR
Quarterly revenue: INR 6,694 crores (+7% YoY)
EBITDA MARGIN: 25.6%
EBITDA margin: 25.6% (+154 bps YoY)
NORTH AMERICA REVENUE:
North America revenue: $250 million (+13% YoY)
INDIA BRANDED PRESCRIPTION
India branded prescription growth: 10% YoY
stockrabit simplifies the management commentary to help you better understand the industry and sentiments
📊

Financial Performance

revenue growth
"
We reported a quarterly revenue of INR6,694 crores, with a growth of 7%, driven by our core businesses of India, North America and South Africa.
This revenue growth reflects the company's strong performance across key markets despite challenges.
Ashish Adukia
quarterly revenue
Positive High Confidence
EBITDA margins
"
Our EBITDA margins, excluding other income, stood at impressive 25.6% for the quarter, increasing by 154 basis points.
The increase in EBITDA margins indicates improved operational efficiency and profitability.
Ashish Adukia
EBITDA margin
Positive High Confidence
⚙️

Business Operations

"
branded business chronic therapies
Our branded prescription business grew by 10% year-on-year, over a high base of last year with chronic share, further improving by 106 basis points year-on-year to about 61.5%.
This growth in the branded prescription business highlights the company's strong position in chronic therapies.
Ashish Adukia
branded prescription growth
Positive High Confidence
"
North America market position
North America reached all-time high quarterly revenue of $250 million.
This milestone reflects the company's successful strategy in the North American market.
Ashish Adukia
North America revenue
Positive High Confidence
🚀

Growth Initiatives

"
new product launch peptide portfolio
We also launched the generic version of Lanreotide injection during this quarter.
The launch of this significant product is expected to strengthen the company's portfolio in the peptide segment.
Ashish Adukia
Positive High Confidence
"
distribution model operational efficiency
Through the transition of distribution model in the trade generic business, we have increased the direct touch points with the distributors.
This strategic shift aims to deepen channel connections and enhance operational efficiencies.
Ashish Adukia
Positive Moderate Confidence
🌐

Market Dynamics

"
market growth chronic therapies
We continue to outpace market growth in key chronic therapies.
This trend indicates the company's competitive advantage in the chronic therapy segment.
Ashish Adukia
Positive High Confidence
🎯

Future Outlook

"
guidance profitability
As guided, our EBITDA for the year is trending in the range of 24.5% to 25.5% and ROIC is well over 30%.
This guidance reflects management's confidence in maintaining strong profitability and returns on invested capital.
Ashish Adukia
EBITDA guidance
Positive High Confidence
"
regulatory issues operational continuity
Resolution of regulatory issues remains our top priority.
Addressing regulatory challenges is critical for maintaining operational continuity and market access.
Ashish Adukia
Neutral Moderate Confidence